19:19 , Jun 14, 2017 |  BC Innovations  |  Strategy

Threshold to academia

By C. Simone Fishburn, Editor, BioCentury Innovations In transitioning from industry to academia, former CEO of Threshold Pharmaceuticals Inc. Barry Selick wants to walk a fine line between the two worlds, increasing the returns on...
22:54 , Apr 25, 2017 |  BC Extra  |  Company News

UCSF taps Selick for BD position

The University of California San Francisco named Barry Selick vice chancellor for business development, innovation and partnerships. Selick resigned last month as CEO of Threshold Pharmaceuticals Inc. (NASDAQ:THLD). The university said Selick will oversee proof-of-concept...
07:00 , Apr 28, 2016 |  BC Innovations  |  Finance

Bridging translation

An increasing number of academic institutions are filling the translational gap between what typical academic projects produce and what companies or VC firms want to see in order to commercialize a discovery. These organizations, or...
01:22 , Mar 8, 2016 |  BC Extra  |  Financial News

Financial tracks

California Institute for Quantitative Biosciences (QB3) said Douglas Crawford resigned as its associate director at University of California San Francisco. Crawford will continue to be managing director of Mission Bay Capital, QB3's venture fund, and...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Financial News

Symic Biomedical completes venture financing

Symic Biomedical Inc. , San Francisco, Calif.   Business: Autoimmune, Cardiovascular   Date completed: 2015-12-01   Type: Venture financing   Raised: $25 million   Investors: Lilly Ventures; Alexandria Real Estate Equities; Purdue Research Foundation; Den...
01:46 , Dec 2, 2015 |  BC Extra  |  Financial News

Symic raises $25M in series A-2 round

Symic Biomedical Inc. (San Francisco, Calif.) raised $25 million in a series A-2 round led by existing investor Lilly Ventures. New investors Alexandria Real Estate and Purdue Research Foundation also participated, as did existing investors...
08:00 , Nov 19, 2015 |  BC Innovations  |  Tools & Techniques

Bell's magnetic organelles

With FDA calling for non-invasive new tracking systems to accompany cell therapies, Bell Biosystems Inc. wants its Magnelle trackers to become the technology of choice. While the magnetic organelles' longevity and strong signals lend the...
07:00 , Oct 15, 2015 |  BC Innovations  |  Finance

Public-Private Partnership Roundup

PPP activity was down slightly in 3Q15 compared with the previous quarter, with 61 partnerships announced during that span. Big pharmas and biotechs continue to pair up with public and academic institutions at a high...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Company News

QB3, GlaxoSmithKline deal

QB3@953, an incubator created by QB3, partnered with GlaxoSmithKline to identify and facilitate partnerships for drug development. QB3@953 will provide lab facilities and services, and GSK will contribute its “drug discovery and development capabilities.” California...
07:00 , Apr 16, 2015 |  BC Innovations  |  Finance

Public-Private Partnership Roundup

PPP activity in 1Q15 picked up where it left off at the end of last year, with 54 new partnerships disclosed, and big pharmas or biotechs accounting for 20 of those collaborations. AstraZeneca plc led...